Bali International Hospital
Bali, 19 June 2024, Bali International Hospital, a subsidiary of PT Pertamina Bina Medika Indonesia Healthcare Corporation (“IHC”), and Icon Asia Holdings Pte Ltd (“ICON”), a subsidiary of global cancer care provider Icon Group ̶ Australia’s largest provider of private cancer care services – has signed a Memorandum of Understanding (“MOU”) on 6 June, 2024 to enhance the quality of oncology care for the people of Indonesia.
The MOU was signed by dr. Dewi F. Fitriana, MPH, Chief Executive Officer of Bali International Hospital (“BIH”) and Ms. Serena Wee, Chief Executive Officer of Icon ASEAN and Hong Kong, as part of a shared commitment to explore the provision of chemotherapy compounding, oncology pharmacy, expertise in medical oncology delivery and other oncology services at BIH.
“We recognise the urgent need to address the escalating cancer rates in Indonesia, where it stands as the second leading cause of death among non-communicable diseases,” stated dr. Dewi F. Fitriana, MPH. “Our partnership with Icon marks a crucial step towards bridging the gap in cancer care. Together, we are committed to delivering world-class oncology services that will significantly improve healthcare outcomes for the Indonesian population.”
With over 55 years of expertise in pharmaceuticals, extensive experience in chemotherapy compounding in Australia and New Zealand, and a proven track record in cancer treatment worldwide, Icon brings unparalleled insights to the development of a robust and sustainable oncology model for Indonesia and the wider region.
“At Icon, our mission is to deliver the best care possible, to as many people as possible, as close to home as possible. This MOU enables us to explore opportunities that will increase access to the best-in-class cancer care for Indonesians,” said Ms. Serena Wee, Chief Executive Officer of Icon ASEAN and Hong Kong.
Advanced technology and equipment will underpin the BIH cancer care offering, including 3D-mammography, 3.0 Tesla MRI, 256-slice CT and a PET-CT to support cancer diagnostics. This will be combined with a Varian TrueBeam and SagiNova Brachytherapy to advance cancer treatment capability. This MOU will enable BIH to leverage Icon’s expertise in establishing world-class oncology services to enable best-in-class, patient-centred care at BIH.
BIH not only aims to improve the quality of healthcare in Indonesia, but also to make Indonesia a global health tourism destination. By combining health tourism and high-quality medicine, BIH is expected to attract tourists and patients from abroad to come to Indonesia.
Bali International Hospital (“BIH”), owned and managed by IHC, is positioned to be Indonesia's leading medical tourism destination. Situated within the newly established Sanur-based Healthcare Special Economic Zone, the hospital encompasses 67,465 square meters spread across four floors. Slated to open in the third quarter of 2024, the hospital will offer 255 beds, 38 intensive care rooms, 8 operating rooms, 4 cath labs, and 5 centres of excellence equipped with advanced diagnostic imaging capabilities.
BIH is organised around specialised centres of excellence, focusing on critical illnesses such as Cardiology, Oncology, and Neurology. Additionally, the hospital will provide services in Gastroenterology, Orthopaedics, and a Medical Check-Up department. A team of expert physicians, surgeons, and staff will deliver patient-centred medical care.
In addition to clinical services, BIH aims to provide a comfortable healing environment rooted in Balinese hospitality. Surrounded by lush greenery, the hospital offers natural spaces where patients can experience tranquility along the Sanur coastline. This commitment underscores the hospital’s dedication to holistic patient care and well-being.
Icon Group is Australia's largest integrated cancer care provider with a growing presence in New Zealand and Asia.
Icon is built on a strong but simple mission - to deliver the best possible care to as many people as possible, as close to home as possible.
The group brings together all aspects of quality cancer care including medical oncology, hematology, radiation oncology, research, pharmacy and pharmaceutical services in chemotherapy to provide a truly integrated and comprehensive service for cancer patients.
Today, Icon has served more than 3.5 million patient interactions across more than 50 cancer centers, five compounding facilities, and manages more than 70 pharmacies. Supported by a network of more than 300 physicians, Icon delivers world-leading services and helps address the global cancer burden
With a strong focus on innovation and investment in technology-based solutions, as well as partnerships with leading international bodies such as the Union for International Cancer Control, Icon is proud to be at the forefront of addressing the global cancer burden.
